Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods Under Section 41

Overview

The Therapeutic Goods Act 1989 was enacted to provide a comprehensive regulatory framework for therapeutic goods, including medicines, medical devices, and blood products, in Australia. This legislation was introduced to address the need for a unified system to ensure the safety, quality, and efficacy of therapeutic goods available in the market. The Act is administered by the Therapeutic Goods Administration (TGA), a statutory body within the Department of Health, with the overarching policy objective of protecting public health by regulating therapeutic goods in Australia. This particular Gazette publication by the Delegate of the Secretary of the Department of Health, Therapeutic Goods Administration, concerns the revocation of licences to manufacture therapeutic goods, which is a regulatory action taken to maintain high standards of quality and safety in the manufacture of these goods.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) under the Commonwealth of Australia’s Department of Health, applies to the regulation of therapeutic goods, including medicines, medical devices, blood, and tissues within Australia. This Act encompasses various entities such as manufacturers, importers, sponsors, and suppliers of therapeutic goods, ensuring that these goods meet safety, quality, and efficacy standards before they can be supplied in Australia. The Act's jurisdictional reach is national, applying to all therapeutic goods across the Commonwealth, states, and territories of Australia. Notably, the Act includes provisions for the revocation of manufacturing licences, as evidenced by the revocation notices published for several companies at the request of the manufacturers themselves. This revocation process is conducted under Section 41 of the Act, which allows the Secretary to revoke a licence if certain conditions are met. The application of the Act can be further extended or specified through subordinate instruments, which provide additional regulations and guidelines to ensure compliance with the overarching legislative framework.

Key Provisions

The Therapeutic Goods Administration (TGA) has published details under Section 41 of the Therapeutic Goods Act 1989 concerning the revocation of licences for the manufacture of therapeutic goods. This revocation affects several entities, including Selborne Biological Services (Australia) Pty Ltd (Section 41(1)(d)), Grifols Australia Pty Ltd, The Australian Red Cross Blood Service, and Merck Sharp & Dohme Australia Pty Ltd, among others. Each of these companies requested the revocation of their manufacturing licences, which are identified by their respective licence numbers and addresses. The obligations imposed on the entities governed by this Act primarily revolve around ensuring the quality and safety of therapeutic goods. These obligations include complying with manufacturing standards, maintaining proper records, and adhering to any specific requirements set forth by the TGA. The revocation of the licences means that these entities are no longer authorised to manufacture therapeutic goods and must cease any such activities immediately. The manufacturers are required to notify the TGA of the cessation of their manufacturing operations and must ensure that any ongoing or incomplete manufacturing processes are managed appropriately. Breaching the provisions of the Therapeutic Goods Act 1989 can lead to various civil and criminal consequences. For instance, if a person or entity continues to manufacture therapeutic goods without a valid licence, they could be subject to fines and penalties. The maximum penalties for such offences can be substantial, reflecting the serious nature of ensuring public safety in relation to therapeutic goods. Criminal penalties may include imprisonment, while civil penalties can involve significant financial penalties. These measures are designed to enforce compliance and deter non-compliance with the Act’s requirements.